Breaking News
Subscribe Now 0
🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAY
CLAIM SALE
Close

AstraZeneca PLC (A1ZN34)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
61.97 -1.33    -2.10%
17:11:32 - Delayed Data. Currency in BRL
Type:  Equity
Market:  Brazil
ISIN:  BRA1ZNBDR003 
  • Volume: 744
  • Bid/Ask: 61.68 / 61.80
  • Day's Range: 61.68 - 63.84
AstraZeneca 61.97 -1.33 -2.10%

A1ZN34 Financial Summary

 
A brief financial summary of AstraZeneca PLC as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

AstraZeneca PLC reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 482 million compared to USD 341 million a year ago. Revenue was USD 12,938 million compared to USD 11,416 million a year ago. Net income was USD 1,927 million compared to USD 1,818 million a year ago. Basic earnings per share from continuing operations was USD 1.24 compared to USD 1.17 a year ago. Diluted earnings per share from continuing operations was USD 1.24 compared to USD 1.17 a year ago.For the six months, sales was USD 939 million compared to USD 627 million a year ago. Revenue was USD 25,617 million compared to USD 22,295 million a year ago. Net income was USD 4,106 million compared to USD 3,621 million a year ago. Basic earnings per share from continuing operations was USD 2.34 compared to USD 2.65 a year ago. Diluted earnings per share from continuing operations was USD 2.32 compared to USD 2.63 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

A1ZN34 Income Statement

Gross margin TTM 82.62%
Operating margin TTM 25.13%
Net Profit margin TTM 13.11%
Return on Investment TTM 14.32%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 12938 12679 12024 11492
Gross Profit 10771 10481 9729 9437
Operating Income 2900 3310 2034 2533
Net Income 1927 2179 960 1374

A1ZN34 Balance Sheet

Quick Ratio MRQ 0.63
Current Ratio MRQ 0.89
LT Debt to Equity MRQ 69.06%
Total Debt to Equity MRQ 85.15%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 104340 102293 101119 96086
Total Liabilities 64742 64792 61953 58865
Total Equity 39598 37501 39166 37221

A1ZN34 Cash Flow Statement

Cash Flow/Share TTM 7.14
Revenue/Share TTM 31.69
Operating Cash Flow  10.80%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 3085 2486 2380 3114
Cash From Investing Activities -2872 -2413 -1077 -1221
Cash From Financing Activities -1222 2028 -291 -2726
Net Change in Cash -1015 2055 1018 -852
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

A1ZN34 Comments

Write your thoughts about AstraZeneca PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email